People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Athenex, Inc. | — | Pharmaceuticals | Series C | $366.7M | $2.1B | 2016 |
| Sagent Holding Co. | — | Pharmaceuticals | Series B | $45.8M | $204.0M | 2009 |
| Avenacy Inc. | — | Pharmaceuticals | Series B | $26.0M | $156.9M | 2024 |
Jeffrey Yordon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Yordon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Murphy | 1 | 21 |
| Patrick Soon-Shiong | 1 | 16 |
| Chen Yu | 1 | 7 |
| Robert Flanagan | 1 | 4 |
| Johnson Lau | 1 | 3 |
| Simon Pedder | 1 | 3 |
| Charles Lannon | 1 | 3 |
| Douglas Reed Maughan | 1 | 3 |
| Jean-Pierre Sommadossi | 1 | 3 |
| Frank Kung | 1 | 2 |
| Li Shen | 1 | 2 |
| Allen Barnett | 1 | 2 |
| James Hussey | 1 | 2 |
| Flint Besecker | 1 | 1 |
| David Hangauer | 1 | 1 |
| David Hsia | 1 | 1 |
| James Sperans | 1 | 1 |
| Joe Reed Mase | 1 | 1 |
| Lyn Dyster | 1 | 1 |
| Jinn Wu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.